EFFECT OF METHYL TESTOSTERONE ON URINARY
17-KETOSTEROIDS OF ADRENAL ORIGIN 1, 2, 8

BY E. C. REIFENSTEIN, JR., A. P. FORBES, F. ALBRIGHT, E. DONALDSON,
AND E. CARROLL

(From the Medical Service of the Massachusetts General Hospital and from the Department of
Medicine of the Harvard Medical School, Boston)

(Received for publication July 15, 1944)

Urinary 17-ketosteroids or their precursors are thought to arise from the adrenal cortices and the
testes (1). Testosterone propionate is partially excreted as a 17-ketosteroid (2); on the other hand, 17-methyl testosterone is not excreted as such (3 to 5). It follows that methyl testosterone in contradistinction to testosterone propionate, may be used to study the effect of a testosterone compound on the endogenous production of urinary 17-ketosteroids. The present paper is primarily concerned with the effect of methyl testosterone on the urinary 17-ketosteroids of adrenal origin.

It is essential that such studies be carried out on individuals without functioning testicular tissue, since it is highly probable from animal experiments that testosterone inhibits its own endogenous production in the testis (6 to 8). It is difficult to obtain direct data in humans on the effect of testosterone on the urinary 17-ketosteroids of testicular origin. Thus, whereas the administration of methyl testosterone to a male without disease of the adrenals and testes induced a lowered 17-ketosteroid excretion (Figure 1), the entire effect may have been mediated through the adrenal cortex. Actually to establish the point it would be necessary to give methyl testosterone to a male patient with Addison's disease. This was done (Figures 2 and 3), with suggestive but not conclusive results. Such an experiment runs into difficulties because the low initial level of 17-ketosteroid excretion makes the errors introduced by chromogens and other technical errors relatively more significant.

CLINICAL CASES

The influence of methyl testosterone on 17-ketosteroid excretion by individuals without testicular tissue was studied in 4 females with adrenal hyperplasia, 2 normal females, and 1 male with absence of functioning testicular tissue. Of the 4 patients with hyperplasia, 2 had Cushing's syndrome, and 2, the adenogenital syndrome. Whereas hyperplasia of the adrenal cortices may occur in both of these conditions, it is the authors' belief that in the first of them there is primarily an over-production of a hormone concerned with carbohydrate metabolism (the so-called "sugar" or "S" hormone), while in the second there is an over-production of a hormone concerned with anabolism of protoplasm, and masculinization (the so-called "nitrogen" or "N" hormone) (9). In Cushing's syndrome there may be a compensatory over-production of "N" hormone as well (9). One "normal" female had no disease; the other had Paget's disease but was normal with respect to adrenal cortical function. The male patient had clinical evidence of hypoleydigism, a high excretion of follicle-stimulating hormone in the urine, a high 17-ketosteroid excretion, and, as demonstrated at exploration at the age of 8, bilateral rudimentary testes. Thus, the evidence for lack of testicular tissue includes not only the clinical evidence of hypoleydigism and the findings at operation but the high titer of follicle-stimulating hormone (11). The high 17-ketosteroid excretion in spite of the clinical picture of hypoleydigism presumably represents compensatory hyperplasia of the adrenal cortex, such as is known to occur in animals castrated at birth (12, 13). The findings are entirely dissimilar to those in the usual eunuchoid patient, where the follicle-stimulating hormone excretion in the urine is usually normal or low and the 17-ketosteroid is regularly low (14).
EFFECT OF METHYL TESTOSTERONE ON 17-KETOSTEROIDS

In this patient (B. F., No. 36002, a male of 49 years), it is assumed that the functions of the adrenal cortices and testes are comparatively normal; however, the 17-ketosteroid excretion at the time of the experiment was low, probably because of debility (9). It will be noted that, although the control values were low (a mean of 4.8 mgm. per 24 hrs.) compared with the normal level in males (circa 14 mgm. per 24 hrs. (1)), with methyl testosterone therapy there was an orderly fall to a still lower level (a mean of 3.0 mgm. per 24 hrs.), and that with omission of the therapy the values rose to a level (a mean of 5.3 mgm. per 24 hrs.) approximating the pre-treatment level. The values for the first 6 days following a change in therapy were omitted in compiling the mean values. Note that the measurements were made on 24-hour collections.

This patient, K. P., No. 369416, a male of 44 years, had tuberculosis of the adrenals. At the time of the experiment, the patient was taking no medication except 3 grams of sodium chloride by mouth daily. It will be noted that during the control period the 17-ketosteroid excretion was low (a mean of 4.0 mgm. per 24 hrs.) compared with the normal level in males (circa 14 mgm. per 24 hrs. (1)); that under methyl testosterone therapy the level was suggestively lower (a mean of 1.6 mgm. per 24 hrs.); that, when the drug was omitted, the level was increased (a mean of 4.3 mgm. per 24 hrs.). The values for the first 6 days following a change in therapy were omitted in compiling the mean values. Note that the measurements were made on 24-hour collections.
This patient, Mayo Clinic No. 1-269-227, a male of 37 years, had tuberculosis of the adrenals. The data on this patient were made available through the courtesy of Dr. Edwin J. Kepler, Rochester, Minnesota (10), to whom the authors are greatly indebted. During the first 6 days of the experiment, the patient received 10 grams of sodium chloride and 5 grams of sodium citrate by mouth daily; during the remainder of the experiment he was given 4 mgm. of desoxycorticosterone acetate each day intramuscularly. This therapy had no effect on the 17-ketosteroid excretion. It will be noted that during the control period the 17-ketosteroid excretion was low (a mean of 3.5 mgm. per 24 hrs.) compared with the normal level in males \((\text{circa} 14 \text{ mgm. per 24 hrs. } (1))\), and that under methyl testosterone therapy the level was suggestively lower (a mean of 2.1 mgm. per 24 hrs.). The values for the first 6 days following a change in therapy were omitted in compiling the mean values. Note that the measurements were made on 24-hour collections.

**METHODS**

The 17-ketosteroid content of the urine was measured by a method based on a modification (15) of the Zimmernmann reaction (16) that has been described previously (1). To correct the result for color introduced by chromogens, the reaction is read through a green and a violet filter, and a color correction equation applied. The method is accurate within 1 to 2 mgm. in repeated analyses of the same urine pool. Normal females ex-
EFFECT OF METHYL TESTOSTERONE ON 17-KETOSTEROIDS

CUSHING'S SYNDROME
L.G., F., AGE 11

METHYL TESTOSTERONE
50 MG. I.D.

URINARY 17-KETOSTEROID EXCRETION

Fig. 4. Effect of Methyl Testosterone Therapy on the Urinary 17-Ketosteroid Excretion in Case 1, a Girl with Cushing's Syndrome

For discussion, see text. Note that the measurements were made on 72-hour collections until day 42 and on 144-hour collections thereafter.

Methyl testosterone was administered to the patients by mouth in the form of 10 mgm. tablets.

RESULTS

In Case 1, I. G., No. 350260, a girl of 11 years with classical Cushing's syndrome, the effect of methyl testosterone was studied twice (Figures 4 and 5). It will be noted that during both control periods, the 17-ketosteroid excretion (circa 15 mgm. per 24 hours) was very high for her age (normal, circa 1 to 3 mgm. per 24 hours (17)) and quite constant; that under methyl testosterone therapy the excretion showed a very orderly fall to

* Further clinical data are published elsewhere (9).
a considerably lower value (circa 4 mgm. per 24 hours); that, when the therapy was omitted, the excretion again rose.

In Case 2, R. B., No. 3397, a woman of 53 years, also suffering from Cushing's syndrome, it will be observed (Figure 6) that the average pre-treatment excretion (circa 18 mgm. per 24 hours) was high for an adult woman (normal circa 9 mgm. per 24 hours (1)) and very constant; that the excretion rose both with testosterone propionate and with dehydroisoandrosterone acetate; that under methyl testosterone therapy the excretion showed a gradual fall to a low value (circa 2 mgm. per 24 hours); and that, after discontinuation of methyl testosterone therapy, the excretion again rose to the pre-treatment level.

In Case 3, R. H., No. 401611, a girl of 6 years with congenital adrenogenital syndrome and pseudohermaphroditism, it will be noted (Figure 7) that during the control period, the 17-ketosteroid excretion (circa 15 mgm. per 24 hours) was very high for her age; that under methyl testosterone therapy the excretion showed a steady fall to a lower value (circa 10 mgm. per 24 hours); and that after the therapy was omitted the excretion definitely increased.

In Case 4, E. F., No. 240632, a woman of 24 years with a condition similar to Case 3, the average 17-ketosteroid excretion (Figure 8) (circa 45 mgm. per 24 hours) was very high during the control period; with methyl testosterone therapy the average level (circa 35 mgm. per 24 hours) was suggestively lower; and, when the drug was discontinued, the average excretion (circa 40 mgm. per 24 hours) was increased.

Case 5, A. S., a woman of 34 years, had no disease, and normal function of the adrenal cortex. It will be observed (Figure 9) that during the control period the average 17-ketosteroid excretion (circa 11.5 mgm. per 24 hours) was slightly above the average for an adult woman (normal, circa 9 mgm. per 24 hours (1)); that during the administration of 20 mgm. of methyl testosterone daily, the 17-ketosteroid excretion tended to be lower; that during the administration of 40 mgm. of methyl testosterone daily, the excretion showed a gradual fall to definitely low values (circa 6 mgm. per 24 hours); and that after discontinuation...
Fig. 6. Effect of Testosterone Propionate, Dehydroisoandrosterone Acetate, and Methyl Testosterone Therapy on the Urinary 17-Ketosteroid Excretion in Case 2, a Woman, Age 53 Years, with Cushing's Syndrome

For discussion, see text. Note that the measurements were made on 16- to 24-hour collections.
ADRENO-GENITAL SYNDROME
R.H. Φ AGES 6

METHYL TESTOSTERONE
50 MG. I.D.

URINARY 17 KETOSTEROID EXCRETION

MG/24 HR.

DAYS

FIG. 7. EFFECT OF METHYL TESTOSTERONE THERAPY ON THE URINARY 17-KETOSTEROID EXCRETION IN CASE 3, A GIRL WITH ADRENOGENITAL SYNDROME

For discussion, see text. Desoxycorticosterone acetate, 10 mgm. daily, was given intramuscularly from day 66 to day 86. This therapy had no effect on the 17-ketosteroid excretion. Note that the measurements were made on 24-hour collections for the first 3 and the last 3 determinations, on 72-hour collections for days 18 to 24, and otherwise on 144-hour collections.

tion of methyl testosterone therapy, the excretion again rose to the pre-treatment level.

Case 6, F. S., No. 424919, a woman of 35 years with Paget's disease (osteitis deformans), is assumed to have normal function of the adrenal cortex. It will be seen (Figure 10) that, during the control period, the 17-ketosteroid excretion (*circa* 8 mgm. per 24 hours) was approximately average for an adult woman (normal *circa* 9 mgm. per 24 hours (1)); and that under methyl testosterone therapy the level (*circa* 6 mgm. per 24 hours) was moderately but hardly significantly lower.

Case 7, F. B., No. 84187, a man of 27, had before any specific treatment a high voice, small larynx, no beard, rudimentary prostate, absence of testes in scrotum, moderately well developed phallus, axillary and pubic hair absent, scant hair on extremities, absence of recession of hair in temporal regions, and obesity. Bilateral rudimentary testes were found at operation at age of 8. The pituitary gonadotropic (follicle-stimulating) hormone in the urine (between 567 and 868 mouse units per 24 hours) was very high compared with the normal (less than 104 mouse units per 24 hours (19)). The excretion of 17-ketosteroids (*circa* 16 to 33 mgm. per 24 hours) was also high. It will be noted (Figure 11), that two experiments were carried out on this patient with different doses of methyl testosterone. The control values (*circa* 24 mgm. per 24 hours) were high; during the administration of 100 mgm. of
EFFECT OF METHYL TESTOSTERONE ON 17-KETOSTEROIDS

For discussion, see text. Note that the measurements were made on 24-hour collections.

methyl testosterone daily there was a fall to a lower level (circa 19 mgm. per 24 hours); during the 14 days after the cessation of therapy, the level (circa 18 mgm. per 24 hours) continued low. This experiment was considered inconclusive and so was repeated with larger doses. During the administration of 200 mgm. of methyl testosterone daily, the 17-ketosteroid excretion (circa 10 mgm. per 24 hours) was definitely lower than the initial values (circa 24 mgm. per 24 hours) or the intervening control values (circa 18 mgm. per 24 hours); from the 14th to 27th day following cessation of treatment, the level (circa 18 mgm. per 24 hours) was significantly higher. It will be noted in Figure 11 that chorionic gonadotropin (A.P.L.) was administered on two occasions. Although this therapy may have induced a transitory rise in the 17-ketosteroid excretion, this possibility has been ignored in compiling the mean values obtained during methyl testosterone therapy (Table I).

The data from these studies are summarized in Table I. Since there is a delay in the onset and in the cessation of effect following the adminis-
tration of methyl testosterone, the values for the first 6 days following a change in therapy were omitted in compiling the mean values. In the 9 experiments, the 7 patients had an average excretion of 18.7 mgm. of steroid per 24 hours before, 11.9 mgm. during, and 18.4 mgm. after methyl testosterone administration.

**DISCUSSION**

The possibility that the decrease in the urinary 17-ketosteroid level during the administration of methyl testosterone is fortuitous and unrelated to the therapy is almost eliminated by the following points: (a) there is a direct relationship between the fall in level and the administration of the therapy, which is clear-cut in Case 1 (both experiments), Case 2, Case 3, Case 5, and Case 7 (Experiment 2); (b) there is a tendency toward a fall in the excretion in all of the other experiments (including the studies of the two males with Addison's disease, and of the male with normal function of the adrenals and of the testes); (c) the fall in the level is gradual suggesting a physiologic alteration rather than a chance variation; (d) there is a rebound to higher or pre-treatment levels with cessation of therapy in all of the experiments in which these studies were made except Experiment 1, Case 7; and (e) the amount of decrease (circa 40 to 60 per cent) in excretion in Case 1 (both experiments), Case 2, Case 3, Case 5, and Case 7 (Experiment 2) significantly exceeds both the technical errors of the method (*vide supra*) and the amount of unexplained day to day variation (not more than 25 per cent and usually less (20)) that we have encountered elsewhere. For example, 17 assays on one male individual gave an average excretion of 12.9 mgm. per 24 hours with a deviation of ± 1.5 mgm. or
EFFECT OF Methyl TESTOSTERONE ON 17-KETOSTEROIDS

± 12.6 per cent per 24 hours (21). In view of these considerations, it is concluded that the decrease in the urinary 17-ketosteroid level during the administration of methyl testosterone is due to the action of this compound.

Much of the argument to follow depends on the assumption that the 17-ketosteroid excretion in the urine can be used as a measure of "S" or "N" hormone production. We have elsewhere (9) reviewed the considerable circumstantial evidence that the urinary 17-ketosteroids are: (a) largely derived from "N" hormones, and (b) only slightly, if at all, from "S" hormones. We will cite here only one piece of evidence for each of these suppositions. Thus, on the one hand, testosterone (a strong "N" hormone) is excreted largely as androsterone and etiocholanolone both of which are 17-ketosteroids; on the other hand, pre-pubertal children, who in all probability have a normal "S" hormone production, excrete negligible amounts of 17-ketosteroids in the urine.

The experiments herein reported indicate that methyl testosterone inhibits the adrenal cortical mechanism for producing urinary 17-ketosteroids or their precursors. Such an interference might be produced in at least two ways: (a) a direct inhibition by methyl testosterone of the adrenal cells which produce 17-ketosteroids or their precursors, or (b) an indirect inhibition of these cells by decreasing the production of some tropic hormone (or hormones) by the anterior pituitary. Animal experimentation favors the latter instead of the former thesis, since it has been shown (22) that the atrophy of the adrenal cortex induced by testosterone therapy does not occur in pituitatectomized animals receiving adrenal corticotropic hormone. This is analogous to experiments of others (6) in which the damaging effects of testosterone on the Leydig cells could not be produced in pituitatectomized animals in which the Leydig cells were maintained by chorionic gonadotropin (a hormone very similar, if not the same, as the luteinizing hormone).

In the case of the male gonad, the tropic hormone in question is the luteinizing hormone, LH. Since it has been shown that methyl testosterone inhibits the 17-ketosteroid production by the adrenal cortex and since the same is thought to be true for the male gonad, these experiments may add one more piece of evidence to that obtained elsewhere (vide infra) that the production of 17-ketosteroids or their precursors from both these organs is stimulated by the same tropic hormone, namely LH.

### Table I

*Effect of methyl testosterone on urinary 17-ketosteroid excretion*

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Average excretion</th>
<th>Before</th>
<th>During</th>
<th>After *</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mgm. per 24 hours</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case 1, Exp. 1</td>
<td>15.3</td>
<td>6.1</td>
<td>13.0</td>
<td></td>
</tr>
<tr>
<td>Case 1, Exp. 2</td>
<td>13.5</td>
<td>7.6</td>
<td>16.3</td>
<td></td>
</tr>
<tr>
<td>Case 2</td>
<td>18.7†</td>
<td>5.9</td>
<td>13.2</td>
<td></td>
</tr>
<tr>
<td>Case 3</td>
<td>15.8</td>
<td>11.8</td>
<td>40.1</td>
<td></td>
</tr>
<tr>
<td>Case 4</td>
<td>42.8</td>
<td>34.5</td>
<td>10.2</td>
<td></td>
</tr>
<tr>
<td>Case 5</td>
<td>11.5</td>
<td>6.3‡</td>
<td>18.0</td>
<td></td>
</tr>
<tr>
<td>Case 6</td>
<td>7.6</td>
<td>6.4</td>
<td>18.0</td>
<td></td>
</tr>
<tr>
<td>Case 7, Exp. 1</td>
<td>24.2</td>
<td>18.8§</td>
<td>17.7</td>
<td></td>
</tr>
<tr>
<td>Case 7, Exp. 2</td>
<td></td>
<td></td>
<td></td>
<td>10.0§</td>
</tr>
</tbody>
</table>

* Values during first 6 days after change in therapy omitted.
† Control level before any treatment.
‡ Average during administration of 40 mgm. per day.
§ Values during chorionic gonadotropin therapy included in calculating the average excretion (see Figure 11).
‖ Experiment 2 immediately followed the after-period of Experiment 1 (see Figure 11).
Fig. 11. Effect of Methyl Testosterone Therapy on the Urinary 17-Ketosteroid Excretion in Case 7, Age 27 Years, with Rudimentary Testes
For discussion, see text. Note that the measurements were made on 24-hour collections.
In Figure 12, an attempt is made to show these hormonal relationships schematically in a normal individual; in Figure 13, attempts are made to show these relationships both before and after the administration of methyl testosterone in a normal individual, a female patient with Cushing's syndrome, a female patient with adrenogenital syndrome, and a male patient with Addison's disease.

There is evidence, besides that here presented, that one tropic hormone of the pituitary stimulates in the male both the cells of the adrenal cortices concerned with the production of 17-ketosteroids and the cells of Leydig. In a previous paper from this clinic (14), it was pointed out that those eunuchoid patients (the minority) with high titers of follicle-stimulating-hormone in the urine had 17-ketosteroid excretions of the order of magnitude of those seen in normal females. The inference was that these patients suffered from a primary underfunction of the gonads (i.e., eunuchs from an endocrine point of view) with normal function of the adrenal cortices. It was further shown that those eunuchoid patients (the majority) who did not have a high titer of follicle-stimulating-hormone in the urine had 17-ketosteroid excretions considerably lower than those in the normal female; the inference was that such patients were suffering from a defective production of 17-ketosteroids in both the adrenal cortices and the testes. This suggested that one hormone stimulated both organs (see Figure 12). Furthermore, the failure of bilateral orchidectomy in patients with metastatic cancer of the prostate to lower the 17-ketosteroid excretion (24) is in accord with the suggestion that such a procedure removes an inhibitor to the tropic hormone in question and that the resulting increased production of said tropic hormone stimulates increased production of 17-ketosteroids in the adrenal cortices.

Similarly, the observation that the 17-ketosteroid excretion of young adult females tends to rise for a year or more following termination of ovarian function by castration or X-radiation (25, 26) favors the same interpretation. The demonstration that there is a rise in the urinary excretion of luteinizing hormone in the menopausal state (27) also is in accord with the suggested hypothesis.

---

**FIG. 12. SCHEMATIC DIAGRAM TO SHOW NORMAL RELATIONSHIP BETWEEN ANTERIOR PITUITARY TROPIC HORMONES AND TISSUES PRODUCING 17-KETOSTEROID PRECURSORS**

The pituitary is divided into three compartments: FSH for follicle-stimulating-hormone, LH for luteinizing hormone, and "et al." for remaining hormones. The authors are not certain whether the compartment marked LH should not also include luteotrophin. Striped arrows are used to represent 17-ketosteroid hormones. E—estradiol; P—progesterone; X—hypothetical hormone produced by tubules of testes (23); A—androgin (testosterone); N—"N hormone" (see text); S—"S hormone" (see text).

Other circumstantial evidence that the luteinizing hormone stimulates 17-ketosteroid production by the adrenal cortex is summarized in the following paragraphs. Further discussion of the findings that support these contentions, as well as of a small amount of data that do not, may be found elsewhere (28, 29).

Atrophy of the adrenal cortex has been produced in animals by the administration of testosterone (22, 30 to 40) and progesterone (22, 38, 41, 42); while hypertrophy of the cortex has resulted from treatment with estrogens (43 to 59). These effects cannot be produced in hypophysectomized animals in which the adrenal cortex is maintained in a normal state by the administration of adrenocorticotropic hormone (22, 45, 52, 60). This is evidence that the effects of testosterone, progesterone, and estrogens on the adrenal cortex are brought about through the pituitary. It has been shown that testosterone (6, 38, 61, 62) and progesterone (63 to 66) inhibit the production of luteinizing hormone (LH) by the anterior
pituitary, while estrogens (45, 67 to 69) increase the production of LH. Hypertrophy of the adrenal cortex has been produced by the administration of LH (70), or by substances very analogous to it, such as chorionic gonadotropin (70 to 75) and the gonadotropic principle of pregnant mares' serum (70, 76); presumably atrophy of the adrenal cortex may result from the lack of LH. Further evidence is obtained from the effects of removal of the gonads. Gonadectomy results in an increase in the gonadotropic activity of the pituitary gland (77, 78). Gonadectomy also causes hypertrophy of the adrenal cortex (12, 13, 22, 50, 79 to 88). This hypertrophy of the adrenal cortex can be made to atrophy by testosterone (22, 34, 78, 83, 87, 89, 90) and by progesterone (22, 87); and to increase by estrogens (58, 88). These facts make very attractive the assumption that LH exerts an effect on the adrenal cortex which is characterized by an hypertrophy of the cortex when LH production is excessive, and by an atrophy of the cortex when LH production is diminished below normal.

The question then arises whether the alterations in the adrenal cortex that are attributed to changes in the production of LH by the pituitary cannot be attributed equally well to changes in the production of adrenocorticotropic hormone (ACTH) of the pituitary, since ACTH also exerts an effect on the adrenal cortex which is characterized by a hypertrophy of the cortex when ACTH production is excessive (50, 80, 91 to 105) and by an atrophy of the cortex when ACTH production is diminished below normal (106 to 116). Against this assumption are the following facts: (1) distinct differences can be demonstrated histologically between the hypertrophy of the adrenal cortex produced by the two mechanisms, since in hypophysectomized animals no restoration of the lipid content and no disappearance of the sudanophobe zone occurs after the administration of LH (52, 76) and estrogens (52, 76), while a disappearance of the sudanophobe zone and restoration of the lipid content occurs after the administration of ACTH (52, 76, 101); and (2) hypertrophy of the adrenal cortex has been produced by LH preparations that contain insignificant amounts of ACTH (52, 70, 76), and vice versa (99 to 105). These facts favor the assump-
tion that both LH and ACTH affect the adrenal cortex, but not in the same manner.

The strength of the evidence derived from the animal experiments cited above would be increased if it could be shown that alterations in the size of the adrenal cortex were correlated with changes in the excretion of 17-ketosteroid or androgenic substances. In most of these investigations, this evidence has not been sought. Pertinent to this discussion, however, are the observations of certain investigators (117, 118) who were able to produce significant enlargement of the seminal vesicles and prostates of castrated rats by means of pituitary extracts which also caused hypertrophy of the adrenal cortices. Since the effect could not be elicited in the absence of the adrenals, it is clear that this gland had been stimulated to secrete an androgenic principle. Another author (119) obtained similar results in castrated male guinea pigs, and also observed a masculinizing effect (hypertrophy of the clitoris) with pituitary extracts in ovariectomized females. Studies to demonstrate directly in man the effect of chorionic gonadotropin on the production of 17-ketosteroids by the adrenal cortex are being conducted.

Since the luteinizing hormone in the female stimulates the production of progesterone (120), it might be anticipated that large doses of progesterone (like methyl testosterone) would inhibit 17-ketosteroid production from both the adrenal cortices and the male gonads; studies to answer this question also are being conducted.

The evidence here presented suggests that the high 17-ketosteroid excretion in the adrenogenital syndrome is less easily influenced by methyl testosterone than is that in Cushing's syndrome, even though the pathology in both instances is hyperplasia of the adrenal cortices. This finding is consistent with the thought, already expressed elsewhere (9), that the increased 17-ketosteroid production in Cushing's syndrome is compensatory to the primary pathology which is an increased production of the "S" hormone; such being the case, one would anticipate that when an exogenous source of "N" hormone was made available in the form of methyl testosterone, the endogenous production would quickly recede. In the adrenogenital syndrome, on the other hand, the primary cause of pathology is thought to be a hyperplasia of those cells which produce "N" hormone, and one would anticipate that it would be harder to modify a process which is primary than one which is secondary.

From the clinical point of view, however, the important point is that the over-production of "N" hormone in the adrenogenital syndrome can be reduced. This may be a clue to therapy. Needless to say it is of little value to such a patient to have her endogenous "N" hormone production decreased by taking an exogenous source of "N" hormone. However, if a steroid could be found which inhibits the endogenous source without itself being an androgen, an important advance in the therapy of these unfortunate patients would probably be at hand. Progesterone has not had a beneficial effect in moderate doses (5, 121); it is to be hoped that it may have in very large doses. In any case, the authors feel very strongly that the approach to the problem is in this direction, as nothing is to be gained by subtotal resection of the adrenal cortices (122, 123).

**SUMMARY AND CONCLUSIONS**

1. Since 17-methyl testosterone is not excreted as a 17-ketosteroid, it was employed to study the effect of a testosterone compound on the endogenous production of urinary 17-ketosteroids of adrenal origin.

2. The administration of methyl testosterone decreased the urinary 17-ketosteroids of 7 patients in whom the only source of these substances was the adrenal cortices. The patients included: 2 women with adrenal hyperplasia and Cushing's syndrome, 2 women with adrenal hyperplasia and adrenogenital syndrome, 2 women with normal cortical function, and 1 man with adrenal hyperplasia and congenital absence of functioning testicular tissue.

3. The administration of methyl testosterone caused a suggestive but not conclusive decrease in the urinary 17-ketosteroids of 2 male patients with Addison's disease in whom the only source of these substances was the testes.

4. Since the production of 17-ketosteroids or their precursors by both the adrenal cortex and the male gonad appears to be inhibited by methyl testosterone, it is suggested that the mechanism of inhibition is the same for both glands.
5. This inhibition is attributed to a decreased production of some pituitary tropic hormone, as suggested by animal experiments in the literature. If one accepts this hypothesis, the findings here reported support the thesis that the same tropic hormone, presumably the luteinizing hormone, stimulates both glands.

6. The 17-ketosteroid excretion by patients with the adrenogenital syndrome was less easily influenced by methyl testosterone than was that of patients with Cushing’s syndrome. This is further evidence that the elevated 17-ketosteroid excretion in the former condition is a manifestation of the primary pathology, whereas the increased excretion in the latter condition is an indication of a compensatory process.

7. The fact that the 17-ketosteroid excretion in the adrenogenital syndrome can be reduced with methyl testosterone shows that the condition is potentially reversible and gives hope that a non-androgenic steroid may be found which will likewise reduce the 17-ketosteroid excretion in this condition.

The authors are indebted to Lowell D. Cox for technical assistance.

BIBLIOGRAPHY


   c. Wilkins, L., Idem, Minutes of Fifth Meeting, October 8–9, 1943, p. 132.


5. Unpublished data.


9. Albright, F., Cushing’s syndrome. Its pathological physiology, its relationship to the adrenogenital syndrome, and its connection with the problem of the reaction of the body to injurious agents (“alarm reaction” of Selye). The Harvey Lecture Series, 1942–1943, 38, 123.


15. Callow, N. H., Callow, R. K., Emmens, C. W., and Stroud, S. W., Methods of extracting compounds related to the steroid hormones from human urine. J. Endocrinol., 1939, 1, 76.


41. Clausen, H. J., The atrophy of the adrenal cortex following the administration of large doses of progesterone. Endocrinology, 1940, 27, 989.
44. Burrows, H., Changes induced by oestrogens in adrenals of male mice. J. Path. and Bact., 1936, 43, 121.
52. Golla, Y. M. L., and Reiss, M., Observations on adrenocorticotropic action. J. Physiol., 1941, 100, 1P.
57. Albert, S., and Selye, H., Effect of various pharmacological agents on the morphogenetic actions of
75. de Boissezon, P., The adrenal cortex of the guinea pig and its modifications after injection of urine from pregnant women. Bull. d’histol. appliq. a la physiol., 1936, 13, 129.


121. Talbot, N. B., Personal communication.
